LONA LeonaBio, Inc.
Nasdaq · SEC CIK 1620463 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $99.4K 10 sales by 5 insiders
- Filings on record
- 160 since 2021-07-21, latest 2026-07-10 16:05
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Litton Mark James | Pres, CEO, Dir | — | $45.5K |
| San Martin Javier | Chief MEDICAL Off | — | $20.5K |
| CHURCH KEVIN | CSO | — | $13.3K |
| Worthington Mark | GC, CCO | — | $13.2K |
| Renninger Robert | CFO | — | $6,909 |
| PERCEPTIVE ADVISORS LLC | Dir, 10% | — | — |
Transactions 123
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-06-24 | 2022-06-23 | LONA | Lenington Rachel | COO | S - Sale | $2.69 | -4,193 | 5,807 | -42% | -$11.3K | |
| 2022-06-24 | 2022-06-22 | LONA | Lenington Rachel | COO | A - Grant | $0.00 | +10.0K | 10.0K | New | $0 | |
| M | 2022-06-24 | 2022-05-18+ | LONA | MILESON GLENNA | CFO | A - Grant | $1.04 | +11.7K | 111.8K | +12% | +$12.2K |
| 2022-06-24 | 2022-06-23 | LONA | MILESON GLENNA | CFO | S - Sale | $2.69 | -2,614 | 109.2K | -2% | -$7,032 | |
| M | 2022-06-24 | 2022-05-18+ | LONA | Litton Mark James | CEO, Dir | A - Grant | $0.2575 | +20.8K | 136.5K | +18% | +$5,344 |
| 2022-06-24 | 2022-06-23 | LONA | Litton Mark James | CEO, Dir | S - Sale | $2.69 | -7,960 | 128.6K | -6% | -$21.4K | |
| 2022-06-24 | 2022-06-23 | LONA | CHURCH KEVIN | Executive VP, Research | S - Sale | $2.69 | -2,614 | 57.7K | -4% | -$7,032 | |
| 2022-06-24 | 2022-06-22 | LONA | CHURCH KEVIN | Executive VP, Research | A - Grant | $0.00 | +10.0K | 60.3K | +20% | $0 | |
| M | 2022-06-24 | 2022-05-18+ | LONA | MOEBIUS HANS | Chief Medical Off | A - Grant | $1.03 | +11.7K | 33.0K | +55% | +$12.0K |
| D | 2022-06-10 | 2022-06-08 | LONA | CHURCH KEVIN | Executive VP, Research | M - OptEx | $1.35 | +2,500 | 50.3K | +5% | +$3,375 |
| D | 2022-06-10 | 2022-05-18 | LONA | CHURCH KEVIN | Executive VP, Research | A - Grant | $7.06 | +243 | 47.8K | +0.5% | +$1,716 |
| D | 2022-04-12 | 2022-04-11 | LONA | MILESON GLENNA | CFO | M - OptEx | $10.64 | +3,000 | 100.1K | +3% | +$31.9K |
| 2022-04-01 | 2022-03-31 | LONA | Romano Kelly A | Dir | P - Purchase | $13.11 | +8,000 | 8,315 | +2,540% | +$104.9K | |
| D | 2022-02-18 | 2022-02-18 | LONA | CHURCH KEVIN | Executive VP, Research | M - OptEx | $1.19 | +3,152 | 47.6K | +7% | +$3,751 |
| D | 2022-01-31 | 2021-11-18 | LONA | Litton Mark James | CEO, Dir | A - Grant | $12.51 | +885 | 115.8K | +0.8% | +$11.1K |
| D | 2022-01-20 | 2021-11-18 | LONA | MOEBIUS HANS | Chief Medical Off | A - Grant | $12.51 | +829 | 31.3K | +3% | +$10.4K |
| D | 2022-01-20 | 2021-11-18 | LONA | CHURCH KEVIN | Executive VP, Research | A - Grant | $12.51 | +96 | 44.4K | +0.2% | +$1,201 |
| D | 2022-01-06 | 2021-11-18 | LONA | MILESON GLENNA | CFO | A - Grant | $12.51 | +931 | 90.8K | +1% | +$11.6K |
| D | 2022-01-06 | 2022-01-04 | LONA | MILESON GLENNA | CFO | M - OptEx | $1.35 | +6,305 | 97.1K | +7% | +$8,512 |
| D | 2021-08-19 | 2021-05-18 | LONA | Litton Mark James | COO | A - Grant | $14.45 | +867 | 64.4K | +1% | +$12.5K |
| D | 2021-08-19 | 2021-08-17 | LONA | Litton Mark James | COO | M - OptEx | $1.35 | +50.4K | 114.9K | +78% | +$68.1K |
| DM | 2021-07-21 | 2021-07-21 | LONA | MOEBIUS HANS | Chief Medical Off | M - OptEx | $1.35 | +28.4K | 30.4K | +1,381% | +$38.3K |
| D | 2021-07-21 | 2021-05-18 | LONA | MOEBIUS HANS | Chief Medical Off | A - Grant | $14.45 | +2,055 | 2,055 | New | +$29.7K |
Purchase Sale Sale after option exercise All abbreviations